Cargando…
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in combination with chemotherapy have become the standard of care in the first-line treatment strategy of advanced non-small cell lung cancer (NSCLC) patients. Combination treatment with ICI, such as nivolumab and ipil...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549681/ https://www.ncbi.nlm.nih.gov/pubmed/31213908 http://dx.doi.org/10.2147/CMAR.S164935 |